Modality
Cell Therapy
MOA
KRASG12Ci
Target
PD-1
Pathway
DDR
Urothelial Ca
Development Pipeline
Preclinical
Dec 2017
→ Jan 2028
PreclinicalCurrent
NCT06172539
2,143 pts·Urothelial Ca
2017-12→2028-01·Not yet recruiting
NCT08872861
2,862 pts·Urothelial Ca
2020-11→2025-08·Not yet recruiting
5,005 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-08-167mo agoInterim· Urothelial Ca
2028-01-131.8y awayInterim· Urothelial Ca
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
Preclinical
Not yet…
Preclinical
Not yet…
Catalysts
Interim
2025-08-16 · 7mo ago
Urothelial Ca
Interim
2028-01-13 · 1.8y away
Urothelial Ca
Not yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06172539 | Preclinical | Urothelial Ca | Not yet recr... | 2143 | UPCR |
| NCT08872861 | Preclinical | Urothelial Ca | Not yet recr... | 2862 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 |